Is Wegovy a Single-Use Pen, and How Does the Pen Format Work?

What the MHRA's approval of the 7.2mg pen confirmed about single-use design

The MHRA approved the dedicated single-dose 7.2mg Wegovy pen on 14 April 2026, and the gov.uk announcement spelled out the design clearly: one pre-set weekly injection, an auto-dosing mechanism, a built-in covered needle, and a lock that activates after use. That lock is the single-use principle made physical, once the pen has fired, it cannot be reset or reloaded. This was already true of the earlier pen strengths (0.25mg through 2.4mg), where each pen contains four weekly doses only if the barrel is of that older multi-dose configuration, but the 7.2mg pen brings everything into one fully integrated, single-injection device.

It is worth being precise about the distinction. Earlier Wegovy pens in the titration schedule each contain enough semaglutide for one dose at that strength, with a separate needle that must be attached before injecting. The 7.2mg pen is structurally different: the needle is concealed and built in, the dose is fixed, and the mechanism locks on completion. Both formats are single-use in the sense that one pen equals one weekly dose. The full guide to Wegovy pens covers the physical differences between strengths in more detail.

The MHRA approved the 7.2mg pen specifically for adults with obesity (BMI 30 or above). It is not approved for the cardiovascular indication or for people with a BMI below 30. Treatment still starts at 0.25mg and titrates upward at roughly four-week intervals, so 7.2mg is the ceiling after a lengthy, prescriber-managed journey. The gov.uk news page on the 7.2mg pen approval has the full regulatory detail.

Does single-use mean a new needle every time?

For the pre-7.2mg strengths, yes, fitting a fresh needle before each injection is part of the correct technique. Needles should never be reused between doses, and compatible replacement needles are available if you need them. The 7.2mg pen removes this step because its needle is sealed inside the device, so there is nothing to attach or change.

Injection site hygiene is separate from the needle question. Cleaning the skin with an alcohol swab before each injection remains good practice regardless of which pen strength you are using. The step-by-step injection technique guide walks through site preparation, rotation between the abdomen, thigh and upper arm, and what to do if a dose is missed, though for missed doses and anything involving timing, your prescriber and the Patient Information Leaflet in the box are always the right source.

The auto-dose lock on the 7.2mg pen also reduces the risk of accidental double-dosing, which matters because semaglutide is measured with precision at every step of the titration. A pen that cannot be re-triggered after firing is a practical safety feature, not just a packaging choice. If you are moving up to 7.2mg from 2.4mg, your prescriber will have reviewed that step before it happens. Specific dose availability at any strength is confirmed at consultation.

Disposing of a single-use pen safely

Used Wegovy pens are clinical sharps and must not go into a household recycling bin or general rubbish. A rigid, puncture-resistant sharps container is the correct disposal route, your local pharmacy or GP surgery can advise on collection points near you. This applies to both the older needle-and-pen format and the 7.2mg auto-lock pen, even though the needle on the latter is fully retracted after use.

Disposal is easy to overlook when everything else about the pen is designed to be low-effort. Your pen arrives through DPD in plain, unmarked packaging, it goes straight into the fridge, comes out on your injection day, and once used it goes straight into your sharps bin. That rhythm becomes second nature quickly. For storage specifics, Wegovy must be kept refrigerated and the exact room-temperature window is detailed in the Patient Information Leaflet; the Wegovy storage guide covers the practical questions that come up most often.

If you're not yet on Wegovy and want to understand whether it would be clinically appropriate for you, the weight-loss treatment overview explains how the licensed options compare. Semaglutide (Wegovy) and tirzepatide (Mounjaro) are both prescription-only and require a clinical assessment, a prescriber decides suitability based on your health picture, not just your BMI. You can also read about how Wegovy is prescribed privately in the UK, including what the assessment involves. The NHS semaglutide medicines page covers the clinical background in straightforward terms.

For anyone already prescribed Wegovy and working through the titration schedule, guidance for your first injection is available, along with detailed pen use instructions if you want a full walkthrough before you start. Our clinical team is reachable seven days a week for aftercare questions once you're a patient.